Expression Analysis Announces 2014 Grant Winners
January 15 2015 - 8:00AM
Business Wire
Awards will Support Colorectal and Ovarian
Cancer Research
Expression Analysis (EA), a Quintiles company, today announced
the winners of a grant program that provides scientists with
leading-edge products and services to advance genomics research. In
this sixth year of the program, EA and co-sponsor, Illumina,
awarded two fully funded research grants to investigate genomic
data locked within Formalin-Fixed, Paraffin Embedded (FFPE) tumor
samples – a largely untapped data pool that can help enhance
researchers’ understanding of cancer biology.
Anne Bowcock, recipient of an EA grant
(Photo: Business Wire)
After a rigorous review of nearly 700 submissions by a
distinguished panel of judges, two researchers were selected to
receive grants. The recipients include:
- Professor Anne Bowcock, Ph.D., chair of
Cancer Genomics at Imperial College London, who will profile a
specific subset of metastatic colon cancers – those that
metastasize to the lung – for CpG methylation and transcriptomic
alterations. Her research, driven in partnership with Sing Yu
Moorcraft and Ian Chau, will help create a comprehensive profile of
genomic changes that occur during tumor evolution. These results
could help inform the identification of drugs that target key
abnormalities and molecular drivers of this often-deadly cancer.
They could also help identify potential prognostic or predictive
biomarkers that can assist physicians in determining optimal
treatment approaches.
- Dr. Zhiqing Huang, M.D., Ph.D., senior
research scientist at the Duke University Medical Center, will
investigate genome-scale DNA methylation and RNA expression changes
in epithelial ovarian cancer to help explain ovarian cancer
recurrence and the contribution of the tumor microenvironment.
These results could help identify new biomarkers for ovarian cancer
diagnosis and prognosis, especially among the 20-30 percent of
ovarian cancer patients whose tumors do not produce CA125 – a key
biomarker for ovarian cancer diagnosis known today. In addition,
they hope to identify more relevant targets for chemotherapy or
gene-specific therapy.
“Genomic research has the power to transform our knowledge of
cancer biology and is instrumental in identifying biomarkers that
lead to the development of life-saving and life-enhancing
therapies,” said Kellie Yarnell, vice president for Genomic
Operations at EA. “Through this grant program, we will help support
the work of Dr. Bowcock and Dr. Huang, whose research could one day
lead to important advances in the fights against colorectal and
ovarian cancers.”
“We are honored to support the efforts of Dr. Bowcock and Dr.
Huang in their quests to better understand the underlying science
of colon and ovarian cancers. We hope that their research yields
insights which will one day improve outcomes for individuals with
these devastating diseases,” said Tina Nova, senior vice president
and general manager, oncology for Illumina.
About EA
EA, a Quintiles company, provides cutting-edge genomic
sequencing, gene expression, genotyping, and bioinformatics
services to the world’s largest pharmaceutical companies,
diagnostic test developers, government agencies, and academic labs.
Projects are conducted under clinical-grade quality control,
ensured through CLIA certification, GCP compliance, and adherence
to CLSI guidelines as applicable to the testing performed. EA’s
bioinformatics staff are key contributors to the Food and Drug
Administration’s MicroArray Quality Control (MAQC) and Sequencing
Quality Control (SEQC) studies, which aim to improve standards and
quality measures for reliable use of next-generation sequencing and
gene expression technologies in clinical practice and regulatory
decision-making. As part of its mission to improve human health, EA
has donated more than $2.8 million towards academic genomic
research grants and its “Leave Your Fingerprint on the Cure”
Program for pediatric cancer hosted at the American Society for
Human Genetics annual meeting.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top-100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare outcomes. To
learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for
Quintiles.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20150115005099/en/
QuintilesMari Mansfield, Media Relations+1-919-998-2639
(office), +1-919-259-3298
(mobile)mari.mansfield@quintiles.comorKarl Deonanan, Investor
Relations+1-919-998-2789InvestorRelations@quintiles.comwww.quintiles.com
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Apr 2024 to May 2024
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From May 2023 to May 2024